{
    "clinical_study": {
        "@rank": "134625", 
        "arm_group": [
            {
                "arm_group_label": "Genotype 4: Treatment-naive", 
                "arm_group_type": "Experimental", 
                "description": "Treatment-naive participants with HCV genotype 4 will receive LDV/SOF for 12 weeks."
            }, 
            {
                "arm_group_label": "Genotype 4: Treatment-experienced", 
                "arm_group_type": "Experimental", 
                "description": "Treatment-experienced participants with HCV genotype 4 will receive LDV/SOF for 12 weeks."
            }, 
            {
                "arm_group_label": "Genotype 5: Treatment-naive", 
                "arm_group_type": "Experimental", 
                "description": "Treatment-naive participants with HCV genotype 5 will receive LDV/SOF for 12 weeks."
            }, 
            {
                "arm_group_label": "Genotype 5: Treatment-experienced", 
                "arm_group_type": "Experimental", 
                "description": "Treatment-experienced participants with HCV genotype 5 will receive LDV/SOF for 12 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to evaluate the efficacy, safety, and tolerability of ledipasvir/sofosbuvir\n      (LDV/SOF) fixed-dose combination (FDC) in participants with chronic genotype 4 or 5\n      hepatitis C virus (HCV) infection as measured by the proportion of subjects with sustained\n      virologic response (SVR12), defined as HCV RNA < lower limit of quantification (LLOQ) 12\n      weeks after discontinuation of therapy."
        }, 
        "brief_title": "Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Treatment-Na\u00efve and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV Infection", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chronic Genotype 4 HCV", 
            "Chronic Genotype 5 HCV"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  HCV RNA \u2265 104 IU/mL at Screening\n\n          -  Chronic genotype 4 or 5 HCV Infection\n\n          -  Subjects may be treatment na\u00efve or treatment experienced\n\n          -  Presence or absence of cirrhosis, a liver biopsy may be required\n\n          -  Healthy according to medical history and physical examination with the exception of\n             HCV diagnosis\n\n          -  Agree to use two forms of highly effective contraception for the duration of the\n             study\n\n        Exclusion Criteria:\n\n          -  History or current evidence of any condition, therapy, laboratory abnormality or\n             other circumstance that might confound the results of the study, or interfere with\n             the subject's participation for the full duration of the study or not be in the best\n             interest of the subject in the opinion of the investigator\n\n          -  Prior exposure to approved or experimental HCV specific direct acting antiviral(s)\n             (DAA(s)) other than NS3/4A protease inhibitors\n\n          -  History of any other clinically significant chronic liver disease\n\n          -  Evidence of or history of decompensated liver disease\n\n          -  HIV or chronic hepatitis B (HBV) infection\n\n          -  Hepatocellular carcinoma (HCC) or other malignancy (with exception of certain\n             resolved skin cancers)\n\n          -  Chronic use of immunosuppressive agents or immunomodulatory agents"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02081079", 
            "org_study_id": "GS-US-337-1119", 
            "secondary_id": "2013-003978-27"
        }, 
        "intervention": {
            "arm_group_label": [
                "Genotype 4: Treatment-naive", 
                "Genotype 4: Treatment-experienced", 
                "Genotype 5: Treatment-naive", 
                "Genotype 5: Treatment-experienced"
            ], 
            "description": "LDV 90 mg / SOF 400 mg FDC tablet administered orally once daily", 
            "intervention_name": "LDV/SOF", 
            "intervention_type": "Drug", 
            "other_name": [
                "GS-7977", 
                "PSI-7977", 
                "GS-5885"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "HCV GT 4", 
            "HCV GT 5"
        ], 
        "lastchanged_date": "April 14, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Clermont Ferrand", 
                        "country": "France", 
                        "zip": "63003"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clichy", 
                        "country": "France", 
                        "zip": "92110"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Limoges", 
                        "country": "France", 
                        "zip": "87042"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France", 
                        "zip": "31059"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villejuif", 
                        "country": "France", 
                        "zip": "94800"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 2, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination in Treatment-Na\u00efve and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV Infection", 
        "overall_contact": {
            "email": "GS3371119study@gilead.com", 
            "last_name": "Gilead Study Team"
        }, 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Kathryn Kersey, MSc", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "SVR12 is defined as HCV RNA < the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.", 
                "measure": "Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)", 
                "safety_issue": "No", 
                "time_frame": "Posttreatment Week 12"
            }, 
            {
                "measure": "Incidence of adverse events leading to permanent discontinuation of study drug", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 12"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02081079"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "SVR4 and SVR24 is defined as HCV RNA < LLOQ at 4 and 24 weeks following the last dose of study drug, respectively.", 
                "measure": "Proportion of participants with sustained virologic response at 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)", 
                "safety_issue": "No", 
                "time_frame": "Posttreatment Weeks 4 and 24"
            }, 
            {
                "description": "Viral breakthrough is defined as having achieved undetectable HCV RNA levels (HCV RNA < LLOQ) during treatment, but did not achieve a sustained virologic response (SVR).", 
                "measure": "Proportion of participants experiencing viral breakthrough", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 12"
            }, 
            {
                "description": "Viral relapse is defined as having achieved undetectable HCV RNA levels (HCV RNA < LLOQ) within 4 weeks of end of treatment, but did not achieve an SVR.", 
                "measure": "Proportion of participants experiencing viral relapse", 
                "safety_issue": "No", 
                "time_frame": "Week 12 to Posttreatment Week 24"
            }, 
            {
                "measure": "HCV RNA change from baseline", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Posttreatment Week 24"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}